QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Writing the Evaluation of Risks and New Information Section in a PBRER

Test your understanding of the concepts covered by Writing the Evaluation of Risks and New Information Section in a PBRER.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What should determine the depth of discussion for a particular important risk?

The number of pages allocated to the risk in the previous PBRER The number of publications found, regardless of their relevance Clinical importance, new evidence, change in understanding, regulatory significance and benefit-risk impact Whether the risk has a short or long preferred term

Question 2 of 10 A registry provides long-term follow-up for an advanced therapy medicinal product in patients underrepresented in trials. Which contribution is most relevant to risk evaluation?

It can help characterise delayed events, durability of safety outcomes and risks in real-world populations It replaces the need to assess spontaneous reports It establishes causality automatically because follow-up is long It is relevant only for estimating commercial sales

Question 3 of 10 Which statement best describes the role of a distributor in relation to PBRER preparation?

A distributor is generally the responsible MAH and must prepare the PBRER A distributor has no role in safety evaluation because it is not usually the MAH A distributor is generally not responsible for preparing the PBRER, but information it provides may need to be incorporated A distributor may replace the MAH's medical assessment when it supplies exposure data

Question 4 of 10 Which approach best demonstrates balanced scientific assessment of an important potential risk?

Presenting only evidence that supports the suspected association Focusing exclusively on spontaneous reports because they generated the concern Considering supportive and contradictory evidence, biological plausibility, study limitations and remaining uncertainty Concluding that uncertainty has ended whenever one study is positive

Question 5 of 10 For a global MAH with regional affiliates, when should regional differences be explicitly discussed in the scientific evaluation?

Whenever any country has a different reporting format Only when a regional affiliate requests separate wording When differences in indications, populations, dosing, formulations or risk minimisation materially affect interpretation of the risk Never, because the PBRER must use only global data

Question 6 of 10 Which conclusion is most appropriate when cumulative evidence confirms the previous characterisation of an important identified risk without materially changing it?

No discussion is needed because no new risk was identified The previous PBRER should be reproduced in full The report should state that the existing understanding remains stable and explain the confirmatory evidence The risk should be downgraded because its profile has not changed

Question 7 of 10 A signal concerning a possible adverse reaction is closed because the current data do not support causality, but exposure remains limited and an ongoing long-term study has not reported. What is the most appropriate PBRER interpretation?

The important potential risk must immediately be removed The signal closure and continued monitoring of the potential risk can both be scientifically justified The concern must be reclassified as an important identified risk The PBRER should omit the issue because the signal is closed

Question 8 of 10 What should a PBRER author do when no regulatory or risk-minimisation action results from the updated evaluation?

Omit the conclusion because no action was taken State that no action is required and link that conclusion to the scientific assessment Automatically introduce an additional PASS Describe the risk as resolved regardless of the evidence

Question 9 of 10 Which element is most important in the interpretation portion of an individual risk discussion?

A chronological list of every source reviewed A medical explanation of what the combined evidence means for causality, risk factors, outcomes or uncertainty A complete reproduction of the reference safety information A list of regulatory decisions without discussion of their evidentiary basis

Question 10 of 10 Why should patient exposure be considered when interpreting changes in adverse event reporting?

Because reporting rates are independent of exposure and exposure is used only for administrative purposes Because an apparent increase in reports may reflect increased use rather than an increased underlying risk Because exposure data determine whether an event is causally related Because exposure information is relevant only to clinical trials

QPPV.com

Knowledge Assessment: Writing the Evaluation of Risks and New Information Section in a PBRER

Cookie Settings